Insights on Treatment‐Free Remission in CML
Webcast
Webcast

Insights on Treatment‐Free Remission in CML

Is It Time to Take the Leap?

View Activity

Not a member of My prIME? Join now for instant access.

The information in this activity is intended for healthcare professionals based outside of the United States. You will be asked to provide your credentials before participating in the activity. This activity may contain information on products outside the approved indications where you practice.

Enhance your understanding of treatment-free remission (TFR) in CML with this webcast of our symposium held during the 19th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy in Estoril. An overview of current chronic myeloid leukemia (CML) treatment approaches in terms of successes and challenges are covered, including criteria to attempt TFR and the appropriate patient selection for and management of patients in TFR.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

IME

IME

Release Date

Release Date

Nov 7, 2017

Expiration Date

Nov 7, 2018

Contemporary treatment of CML: Successes and challenges
Giuseppe Saglio, MD

The rationale and evidence for a TFR approach
Timothy Hughes, MD, FRACP, FRCPA, FAAHMS

From concept to practice: Practical implications and applications of TFR
Delphine Rea, MD, PhD

Decision-Making for TFR Candidates: Practical Examples
Faculty panel discussion

prIME Points™
Timothy Hughes, MD, FRACP, FRCPA, FAAHMS

  • Timothy Hughes, MD, FRACP, FRCPA, FAAHMSUniversity of Adelaide
    Adelaide, South Australia, Australia
  • Delphine Rea, MD, PhDHôpital Saint-Louis
    Paris, France
  • Giuseppe Saglio, MDUniversity of Turin
    Turin, Italy

This educational activity is specifically designed to meet the needs of hematologists and other healthcare professionals involved in the treatment of patients with CML.

The information in this activity is intended for healthcare professionals based outside of the United States. You will be asked to provide your credentials before participating in the activity. This activity may contain information on products outside the approved indications where you practice.

Upon completion of this educational activity, participants should be able to:

  • Describe clinical outcomes associated with current CML treatment approaches in terms of successes and challenges
  • Identify criteria for attempting TFR based on currently available evidence and discuss optimal treatment approaches for achieving these criteria
  • Discuss appropriate patient selection for TFR and management of patients in TFR

This educational activity is supported by a grant from Novartis Oncology.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

This enduring activity is provided by prIME Oncology.

Disclosure Information

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.